Jensen Investment Management Inc. Purchases 930 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Jensen Investment Management Inc. increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.5% during the fourth quarter, HoldingsChannel reports. The fund owned 9,020 shares of the company’s stock after acquiring an additional 930 shares during the quarter. Jensen Investment Management Inc.’s holdings in IDEXX Laboratories were worth $3,729,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Glenview Trust co increased its position in IDEXX Laboratories by 152.8% during the fourth quarter. Glenview Trust co now owns 16,812 shares of the company’s stock worth $6,951,000 after acquiring an additional 10,162 shares during the period. Centurion Wealth Management LLC increased its position in IDEXX Laboratories by 16.4% during the fourth quarter. Centurion Wealth Management LLC now owns 846 shares of the company’s stock worth $350,000 after acquiring an additional 119 shares during the period. Choate Investment Advisors increased its position in IDEXX Laboratories by 1.9% during the fourth quarter. Choate Investment Advisors now owns 2,091 shares of the company’s stock worth $865,000 after acquiring an additional 39 shares during the period. Natixis Advisors LLC increased its position in IDEXX Laboratories by 4.6% during the fourth quarter. Natixis Advisors LLC now owns 45,171 shares of the company’s stock worth $18,675,000 after acquiring an additional 1,997 shares during the period. Finally, Atala Financial Inc bought a new position in IDEXX Laboratories during the fourth quarter worth $102,000. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on IDXX. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Leerink Partners began coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Piper Sandler lifted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Finally, Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Up 2.2 %

Shares of NASDAQ IDXX opened at $415.30 on Monday. The firm’s 50-day simple moving average is $438.03 and its 200 day simple moving average is $446.76. The company has a market cap of $33.78 billion, a price-to-earnings ratio of 38.92, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.